| Project/Area Number |
23591435
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
膠原病・アレルギー・感染症内科学
|
|---|
| Research Institution | Teikyo University (2013)
Tokyo Medical and Dental University (2011-2012) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MIYASAKA Nobuyuki 東京医科歯科大学, 名誉教授 (30157622)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 関節リウマチ / カンナビノイド |
|---|
| Research Abstract |
In this study, we investigated therapeutic effects of a selective cannabinoid receptor 2 (CB2) agonist on arthritis. Immunohistochemistry showed that CB2 was expressed on macrophages, fibroblast-like synoviocytes (FLS) and lymphocytes in the synovial tissues from rheumatoid arthritis (RA). JWH133, a selective CB2 agonist, inhibited IL-6, MMP-3 and CCL2 production from TNF-stimulated FLS, and osteoclastogenesis of peripheral blood monocytes. Administration of JWH133 to murine collagen type II (CII)-induced arthritis (CIA) reduced the arthritis score, inflammatory cell infiltration, bone destruction, and anti-CII IgG1 production. The results suggested that a selective CB2 agonist could be a new therapy for RA that inhibits production of inflammatory mediators from FLS, osteoclastogenesis, and autoantibody production.
|
